Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Better approach for autoimmune pulmonary alveolar proteinosis treatment: inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor: a meta-analyses

Fig. 3

Forest plot shows the pooled outcomes of granulocyte macrophage colony stimulating factor (GM-CSF) therapy in subcutaneous group and inhaled group. a. The response rate of GM-CSF therapy in inhaled group (89%, 95% CI: 71–106%, p < 0.001) was higher than in subcutaneous group (71%, 95% CI: 46–96%, p < 0.001). b. The differences in relapse rate were not significant between inhaled group (19%, 95% CI: 0–37%, p < 0.05) and subcutaneous group (24%, 95% CI: -8-55%, p = 0.14). c. Alveolar oxygen partial pressure (PaO2) improved more in inhaled group (21.02 mmHg, 95% CI: 15.41–26.62, p < 0.001) than in subcutaneous group (8.28 mmHg, 95% CI: 6.30–10.26, p < 0.001) after GM-CSF therapy. d. Alveolar-arterial oxygen gradient (P(A-a)O2) decreased more in inhaled group (19.63 mmHg, 95% CI: 5.82–33.45, p = 0.005) than in subcutaneous group (9.15 mmHg, 95% CI: 7.53–10.78, p < 0.001) after GM-CSF therapy

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us